Home > Resources > Whitepapers > Biodegradation of Fats, Oils, and Greases in Collection Systems

Biodegradation of Fats, Oils, and Greases in Collection Systems

February 10, 2017

We don’t typically think of the wastewater collection system as a biological process, but biological processes are in fact occurring in sewer lines and in related systems such as lift or pump stations. Fecal bacteria are the largest biological inputs into the system. Fecal bacteria are primarily facultative (surviving with or without oxygen sources) and obligate anaerobes (surviving only in the absence of oxygen sources). Microbes are also being contributed from everyday activities (bathing, laundry, food preparation and cleanup, floor mopping, etc.). These microbes may be aerobic (surviving only in the presence of molecular oxygen), facultative, or obligate anaerobes.

Spotlight

Biosceptre International Limited

Biosceptre takes a new approach to precision targeting of P2X7 in cancer, by exploiting a novel variant - "non functional" P2X7 - which has been shown to have a critical role in the survival of many cancer cell types.

OTHER WHITEPAPERS

Internal Co-ordination Group for Biotechnology

whitePaper | October 19, 2022

The Organisation for Economic Co-operation and Development and its member countries have been addressing issues related to biotechnology since 1982.

Making the Promise of mRNA a Reality: OvercomingScale-Up Challenges

whitePaper | March 22, 2023

If scaling issues strike you as obvious or even boring, you should read “On Being the Right Size,” a 1926 essay by geneticist J.B.S. Haldane. It makes the case that a difference in scale—a seemingly simple matter—may demand subtle changes in form and function.

Healthcare system readiness for the adoption of advanced therapies: learnings from the introduction of CAR T cell therapies in the UK

whitePaper | September 17, 2021

The adoption of CAR T therapies in the UK NHS is a success story, especially seen in relation to the experience in many other countries. The UK NHS showed itself to be agile, and responsive to addressing the unique challenges these therapies present, which facilitated access to patients earlier than in many other countries. (including delivery centre selection, development of service specifications, collaboration with manufacturers throughout the preparation phase for adoption, establishment of national multidisciplinary CAR T team to ensure equity of access and prioritization of resources (where needed)).

Benefit-Risk Considerations for Product Quality Assessments; Guidance for Industry; DRAFT GUIDANCE

whitePaper | May 10, 2022

This guidance describes the benefit-risk principles applied by FDA when conducting product quality-related assessments of chemistry, manufacturing, and controls (CMC)2 19 information 20 submitted for FDA assessment as part of original new drug applications (NDAs) under section

U.S. NATIONAL SCIENCE FOUNDATION

whitePaper | August 21, 2022

The “Government Performance and Results Act” and the “GPRA Modernization Act of 2010 require federal agencies to develop strategic plans setting forth long-term goals and objectives. Guidance.

Three Trends to Watch in Life Sciences

whitePaper | June 10, 2022

Healthcare is changing rapidly. Companies who provide products and services to hospitals and physicians will need to adjust their operations to change.